Provided by Tiger Fintech (Singapore) Pte. Ltd.

NovoCure

18.50
-0.0500-0.27%
Post-market: 18.750.2500+1.35%18:03 EDT
Volume:1.01M
Turnover:18.75M
Market Cap:2.03B
PE:-11.83
High:18.97
Open:18.25
Low:17.96
Close:18.55
Loading ...

Why NovoCure Stock Skyrocketed This Week

Motley Fool
·
Yesterday

NovoCure Ltd. Earnings Call: Growth Amid Financial Challenges

TIPRANKS
·
25 Apr

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

Benzinga
·
25 Apr

Novocure’s NSCLC launch momentum ‘positive,’ says H.C. Wainwright

TIPRANKS
·
25 Apr

NovoCure’s Strong Market Penetration and Promising Growth Prospects Justify Buy Rating

TIPRANKS
·
25 Apr

BUZZ-U.S. STOCKS ON THE MOVE- PepsiCo, Procter & Gamble

Reuters
·
24 Apr

Novocure Ltd reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
24 Apr

NovoCure's Q1 Loss Narrows, Revenue Rises

MT Newswires Live
·
24 Apr

BUZZ-Novocure rises after quarterly sales beat

Reuters
·
24 Apr

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

Zacks
·
24 Apr

BRIEF-Novocure Q1 Revenue USD 154.994 Million Vs. IBES Estimate USD 146.6 Million

Reuters
·
24 Apr

Novocure Ltd: Could See an Increase in Import Duties of up to $11 Mln in 2025 IF Tariffs Return to Pre-April 9 Rates

THOMSON REUTERS
·
24 Apr

Novocure Q1 Gross Profit USD 116.473 Million

THOMSON REUTERS
·
24 Apr

Novocure Q1 Revenue USD 154.994 Million VS. Ibes Estimate USD 146.6 Million

THOMSON REUTERS
·
24 Apr

Novocure Q1 Pretax Profit USD -30.295 Million VS. Ibes Estimate USD -44.8 Million

THOMSON REUTERS
·
24 Apr

Novocure Is Maintained at Overweight by Piper Sandler

Dow Jones
·
24 Apr

Novocure to present Phase 3 PANOVA-3 trial results at ASCO 2025

TIPRANKS
·
23 Apr

Novocure to Present Results From the Phase 3 Panova-3 Clinical Trial of Its Tumor Treating Fields (Ttfields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 Asco Annual Meeting

THOMSON REUTERS
·
23 Apr

BUZZ-Novocure rises as lung cancer therapy gets CE mark in Europe

Reuters
·
22 Apr

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Zacks
·
22 Apr